Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies

Oncotarget

Volumn 6, Issue 25, 2015, Pages 21522-21532

  Jäger, Wolfgang ^a,b   Xue, Hui ^c   Hayashi, Tetsutaro ^a   Janssen, Claudia ^a   Awrey, Shannon ^a   Wyatt, Alexander W ^a   Anderson, Shawn ^a   Moskalev, Igor ^a   Haegert, Anne ^a   Alshalalfa, Mohammed ^d   Erho, Nicholas ^d   Davicioni, Elai ^d   Fazli, Ladan ^a   Li, Estelle ^a   Collins, Colin ^a   Wang, Yuzhuo ^a,c   Black, Peter C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d GenomeDx Biosciences Inc   (Canada)

Author keywords

Animal model; Bladder cancer; Muscle invasive bladder cancer; Patient derived cancer xenografts; Targeted therapy

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY R3; UNCLASSIFIED DRUG; FGFR3 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FGFR3 GENE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MOUSE; MUSCLE INVASIVE BLADDER CANCER; MUTATIONAL ANALYSIS; NONHUMAN; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL; BLADDER TUMOR; CANCER TRANSPLANTATION; DISEASE MODEL; DNA MICROARRAY; DNA MUTATIONAL ANALYSIS; DRUG SCREENING; FEMALE; GENETICS; MUTATION; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE;

AGED; ANIMALS; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; MUTATION; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940776859     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3974     Document Type: Article

References (31)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M, European Association of U. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64:639-653.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49:466-477. discussion 475-467.
4. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006; 176:2414-2422. discussion 2422.
5. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365:1273-1283.
6. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23:4602-4608.
7. Chan E, Patel A, Heston W, Larchian W. Mouse orthotopic models for bladder cancer research. BJU Int. 2009; 104:1286-1291.
8. Jager W, Moskalev I, Janssen C, Hayashi T, Awrey S, Gust KM, So AI, Zhang K, Fazli L, Li E, Thuroff JW, Lange D, Black PC. Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach. PLoS One. 2013; 8:e59536.
9. Masramon L, Vendrell E, Tarafa G, Capella G, Miro R, Ribas M, Peinado MA. Genetic instability and divergence of clonal populations in colon cancer cells in vitro. J Cell Sci. 2006; 119:1477-1482.
10. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006; 66:3351-3354. discussion 3354.
11. Guey LT, Garcia-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, Rothman N, Vellalta G, Calle ML, Marenne G, Tardon A, Carrato A, Garcia-Closas R, Serra C, Silverman DT, Chanock S, et al. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol. 2010; 57:283-292.
12. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004; 432:332-337.
13. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res. 2003; 9:845-852.
14. Schumacher U, Adam E, Horny HP, Dietl J. Transplantation of a human ovarian cystadenocarcinoma into severe combined immunodeficient (SCID) mice-formation of metastases without significant alteration of the tumour cell phenotype. Int J Exp Pathol. 1996; 77:219-227.
15. Kiguchi K, Kubota T, Aoki D, Udagawa Y, Yamanouchi S, Saga M, Amemiya A, Sun FX, Nozawa S, Moossa AR, Hoffman RM. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin Exp Metastasis. 1998; 16:751-756.
16. Park B, Jeong BC, Choi YL, Kwon GY, Lim JE, Seo SI, Jeon SS, Lee HM, Choi HY, Lee KS. Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. Cancer Sci. 2013; 104:631-638.
17. Bogden AE, Haskell PM, LePage DJ, Kelton DE, Cobb WR, Esber HJ. Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Exp Cell Biol. 1979; 47:281-293.
18. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res. 2006; 12:4043-4054.
19. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol. 2005; 96:48-55.
20. Hofner T, Macher-Goeppinger S, Klein C, Rigo-Watermeier T, Eisen C, Pahernik S, Hohenfellner M, Trumpp A, Sprick MR. Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer. J Urol. 2013; 190:2263-2270.
21. Chen K, Ahmed S, Adeyi O, Dick JE, Ghanekar A. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PLoS One. 2012; 7:e39294.
22. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507:315-322.
23. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014; 25:152-165.
24. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003; 9:4227-4239.
25. Dong X, Guan J, English JC, Flint J, Yee J, Evans K, Murray N, Macaulay C, Ng RT, Gout PW, Lam WL, Laskin J, Ling V, Lam S, Wang Y. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res. 2010; 16:1442-1451.
26. Sufrin G, McGarry MP, Sandberg AA, Murphy GP. Heterotransplantation of human transitional cell carcinoma in athymic mice. J Urol. 1979; 121:159-161.
27. Piccolo SR, Sun Y, Campbell JD, Lenburg ME, Bild AH, Johnson WE. A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics. 2012; 100:337-344.
28. Mitra AP, Lam LL, Ghadessi M, Erho N, Vergara IA, Alshalalfa M, Buerki C, Haddad Z, Sierocinski T, Triche TJ, Skinner EC, Davicioni E, Daneshmand S, Black PC. Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer. J Natl Cancer Inst. 2014; 106.
29. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005; 24:5218-5225.
30. Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A. 2011; 108:E1275-1284.
31. Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4, 14)-positive multiple myeloma in mice. J Clin Invest. 2009; 119:1216-1229.